The Project Orbis collaborative oncology drug review program has “exceeded our expectations” in terms of encouraging earlier regulatory submissions in Australia, although some challenges remain with regard to issues such as review processes, resources and choice of submission pathway, says a senior official at the country’s Therapeutic Goods Administration.
The TGA has completed 33 submissions under Project Orbis so far, of which 11 have been new molecules and 22...








